Review of Grippol Family Vaccine Studies and Modern Adjuvant Development

Караулов, А. В.; Быков, А. С.; Волкова, Н. В.

doi:10.31631/2073-3046-2019-18-4-101-119

Cited by 10 publications

(5 citation statements)

References 37 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study also obtained data on the activation of TLR3 expressed on granulocytes and lymphocytes after repeated administration of one dose of adjuvanted influenza vaccine (as is recommended according to present guidelines-annually) and on monocytes upon administration of two doses simultaneously and, conversely, the absence of TLR3 activation upon the first vaccination with one dose. Consequently, annual vaccination against influenza using the same adjuvanted vaccine contributes to temporary nonspecific prevention of respiratory infections [57][58][59][60][61][62][63]. Simultaneous administration of two doses of vaccines also contributes to TLR3 expression which is observed only on monocytes, and, probably, the protective effect against other respiratory infections may be less pronounced.…”

Section: Discussionmentioning

confidence: 99%

Expression of Toll-like Receptors on the Immune Cells in Patients with Common Variable Immune Deficiency after Different Schemes of Influenza Vaccination

Kostinova,

Latysheva,

Akhmatova

et al. 2023

Viruses

View full text Add to dashboard Cite

Background: for the first time, the effect of one and two doses of adjuvanted influenza vaccines on toll-like receptors (TLRs) in patients with common variable immunodeficiency (CVID) was studied and compared (primary vaccination with one vs. two doses, primary vs. repeated vaccination). Materials and methods: Six patients received one dose of quadrivalent adjuvanted influenza vaccine during the 2018–2019 and 2019–2020 influenza seasons, and nine patients with CVID received two doses of trivalent inactivated influenza vaccine during 2019–2020. Expression of TLRs was measured by flow cytometry. Results: The expression of toll-like receptors in patients with CVID was noted both with repeated (annual) administration of the influenza vaccine and in most cases was accompanied by an increase in the proportion of granulocytes (TLR3 and TLR9), lymphocytes (TLR3 and TLR8), and monocytes (TLR3 and TLR9). When carried out for the first time as a simultaneous vaccination with two doses it was accompanied by an increase in the proportion of granulocytes, lymphocytes expressing TLR9, and on monocytes—TLR3 and TLR9. Conclusion: in CVID patients, the use of adjuvanted vaccines is promising, and research on the influence of the innate immunity and more effective regimens should be continued.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of Toll-like Receptors on the Immune Cells in Patients with Common Variable Immune Deficiency after Different Schemes of Influenza Vaccination

Kostinova,

Latysheva,

Akhmatova

et al. 2023

Viruses

View full text Add to dashboard Cite

show abstract

“…On a number of model compounds, it was shown that the immunogenicity and protective properties of antigens attached to the Azoximer bromide carrier increase 10-fold with an increase in both the antibody and cell-mediated immune response, the synthesis of all classes of protective antibodies (IgM, IgG, IgA) is enhanced, but the synthesis of allergic IgE antibodies is not stimulated. Thus, some synthetic polyions are strong adjuvants and polyclonal activators of B-and T-lymphocytes ( 41 ). Grippol® plus is produced according to international GMP and ISO ISO:9001 standards in clean rooms on the filling line with hurdle technology, which allows excluding the mercury-containing preservative (thiomersal) from the composition of vaccine.…”

Section: Methodsmentioning

confidence: 99%

Cytokine Profile in Human Peripheral Blood Mononuclear Leukocytes Exposed to Immunoadjuvant and Adjuvant-Free Vaccines Against Influenza

et al. 2020

View full text Add to dashboard Cite

Background: In the last decade, adjuvant-containing vaccines, exerting different effects on the immune system, including the production of cytokines, which are one of the most important regulatory systems of the body, are introduced into practice. Objectives: An effect of the immunoadjuvant polymer-subunit and adjuvant-free vaccines against influenza on the cytokine profile of mononuclear leukocytes in 27 healthy women was studied. Methods: The study of cytokine profile in human peripheral blood mononuclear leukocytes exposed to vaccines against influenza virus was determined by flow cytometry method (Cytomix FC-500, Beckman Coulter, USA) using the Multiplex-13 test system (Bender MedSystems, Austria). Results: It was established that all the studied vaccines leaded to somewhat increased levels of Th1/Th2/Th17/Th9/Th22 cytokines in the culture fluid of peripheral blood mononuclear leukocytes (PBML), which indicates the activation of both humoral and cellular immunity. An immunoadjuvant vaccine has been shown to be superior in activating the synthesis of Th1 (IL-12, INF-g, IL-2, IL-6, IL-1β, TNF-α) cytokines, IL-9 and IL-22, while the subunit vaccine was superior in activating the synthesis of IL-4, and split vaccine—of IL-5. Conclusions: Immunoadjuvant vaccine is superior in terms of inducing cellular immune effectors to a greater extent compared to subunit and split vaccines.

show abstract

“…Furthermore, Grippol® Plus assisted by polymer-based vaccine delivery systems, is in Phase III clinical trial to treat influenza infections [205] . For peptide/protein-based vaccine delivery systems, EBV gp350-Ferritin vaccine developed by NIAID is in Phase I clinical trial for the treatment of Epstein-Barr Virus Infections.…”

Section: Clinical Vaccine Delivery Systemsmentioning

confidence: 99%